Asia-Pacific Radiation Oncology Market Analysis Report 2025-2030 - External Beam Radiation Therapy (EBRT) Dominated the Market with a Revenue Share of 35.9% in 2024
26 nov. 2024 05h18 HE
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Radiation Oncology Market Size, Share & Trends Analysis Report by Type (External Beam Radiation Therapy, Internal Beam Radiation...
Liquid Biopsy Market Size to Worth USD 28.84 Billion by 2033 | Straits Research
21 nov. 2024 09h55 HE
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...
Fight Colorectal Cancer leads Initiative to Improve Quality Care in Colorectal Cancer
20 nov. 2024 08h34 HE
|
Fight Colorectal Cancer
Springfield, Mo., Nov. 20, 2024 (GLOBE NEWSWIRE) -- In response to the persistently high nationwide burden of colorectal cancer (CRC), Fight Colorectal Cancer (Fight CRC) has launched the Colorectal...
Augere Medical secures NOK 23M in the “first close” funding round
19 nov. 2024 04h00 HE
|
Augere Medical AS
OSLO, Norway, Nov. 19, 2024 (GLOBE NEWSWIRE) -- On back of the MDR CE-mark for its Class IIb PolypAID™ system which the company secured in August, Augere has secured NOK 23M (USD 2.1M) for its...
Nouscom Completes Patient Enrollment of Randomized Phase 2 Study Evaluating NOUS-209, an Off-the-Shelf Neoantigen Immunotherapy, in dMMR/MSI Metastatic Colorectal Cancer
19 nov. 2024 02h00 HE
|
Nouscom Srl
Primary efficacy endpoint readout expected in mid-2025Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses...
Artificial Intelligence Revolutionizing the Future of Oncology: Market Set to Soar to US$8.944 Billion by 2029 | 2024 Research Report
14 nov. 2024 10h21 HE
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. The...
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
12 nov. 2024 08h00 HE
|
Compass Therapeutics
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
Fight Colorectal Cancer Rallies Advocates to Vote Ahead of November 5 Election
04 nov. 2024 10h01 HE
|
Fight Colorectal Cancer
Springfield, Mo., Nov. 04, 2024 (GLOBE NEWSWIRE) -- This fall, national nonprofit Fight Colorectal Cancer (Fight CRC) mobilized over 40,000 advocates across the U.S. to prepare for tomorrow’s...
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
30 oct. 2024 16h30 HE
|
Cardiff Oncology, Inc.
- Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in second-line KRAS-mutant mCRC - - Post hoc analysis...
AmMax Bio to Present at the Oppenheimer Healthcare Private Company Showcase
27 sept. 2024 08h33 HE
|
AmMax Bio, Inc.
REDWOOD CITY, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- AmMax Bio, Inc., a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced that it...